While some RNA technology companies are still exploring the accompanying science, Sirnaomics, based in Gaithersburg MD with subsidiaries in Suzhou and Guangzhou, China, has already established 10 pre-clinical and clinical RNA based programs focused on oncology and fibrosis.
Mr. Shaw is a highly regarded biopharmaceutical executive and board member with more than twenty years of financial and strategic leadership experience.
Sirnaomics announced the results showing STP705 inhibits the growth of HuCCt-1 (a human cholangiocarcinoma cell line) as a xenograft tumor in nude mice.
Sirnaomics has sealed the C2 round of financing for $22 million. This round of funding was led by CR-CP Life Sciences Fund, a Hong Kong based joint venture established by China Resources Group and Charoen Pokphand Group, two Asian conglomerates.
Sirnaomics announced that the Company’s management will present its platform technology and discuss the potential clinical utility of RNAi therapeutics at the World Orphan Drug Congress USA 2019 on April 10-12 in Oxon Hill, Maryland.